RedHill Biopharma Ltd. RDHL

Company Overview

RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of therapies primarily targeting gastrointestinal diseases, infectious diseases, and oncology-related conditions. The company operates within the biotechnology and pharmaceutical industries and has historically concentrated on late-stage clinical development, drug commercialization, and repurposed therapeutics. Its revenue has been derived from product sales, licensing arrangements, collaboration agreements, and, in certain periods, milestone-related payments tied to development programs.

The company’s principal products and pipeline assets have included gastrointestinal-focused therapies such as Talicia for Helicobacter pylori infection and Movantik commercialization rights in selected territories, alongside investigational programs targeting COVID-19, inflammatory conditions, and other infectious diseases. RedHill was founded in Israel in 2009 and is headquartered in Tel Aviv, with operations and commercial activities extending into the United States. Over time, the company evolved from a development-stage biotechnology enterprise into a commercially oriented specialty pharmaceutical company through acquisitions, licensing agreements, and commercialization partnerships centered on U.S. specialty markets.